<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of side effects of chemotherapy for early-stage breast cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of side effects of chemotherapy for early-stage breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of side effects of chemotherapy for early-stage breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maryam B Lustberg, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adjuvant chemotherapy results in an improvement in both disease-free and overall survival and is routinely administered for women with early-stage breast cancer. However, treatment is associated with both acute and long-term complications for the breast cancer survivor. The number, nature, and costs of severe adverse effects experienced by women receiving adjuvant chemotherapy for breast cancer are relatively unknown, but may be more common than suspected from what has been reported from clinical trials.</p><p>This was illustrated in a series of 12,239 women aged 63 or younger with newly diagnosed breast cancer between 1998 and 2002, 4075 of whom were treated with adjuvant chemotherapy [<a href="#rid1">1</a>]. Women who were treated with chemotherapy were significantly more likely to visit emergency rooms for all causes (61 versus 42 percent) and for serious adverse effects (16 versus 5 percent). For patients receiving chemotherapy, the major reasons prompting hospitalization or an emergency room visit during the year after their breast cancer diagnosis were:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever or infection</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia or thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Dehydration or electrolyte disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Nausea, emesis, or diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Constitutional symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Deep venous thrombosis or pulmonary embolus</p><p class="bulletIndent1"><span class="glyph">●</span>Malnutrition</p><p></p><p>An overview of acute complications of adjuvant chemotherapy is presented here. Long-term complications and the treatment of breast cancer subsets are discussed separately, as are side effects of hormonal treatments and human epidermal growth factor receptor 2-directed agents. Hypersensitivity reactions associated with chemotherapy are also presented elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a> and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/774.html" rel="external">"Cardiotoxicity of trastuzumab and other HER2-targeted agents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">"Infusion reactions to systemic chemotherapy"</a>.)</p><p></p><p class="headingAnchor" id="H457221093"><span class="h1">SPECIFIC ISSUES RELATED TO INDIVIDUAL AGENTS</span></p><p class="headingAnchor" id="H4008994931"><span class="h2">Taxanes</span><span class="headingEndMark"> — </span>Taxanes are used frequently in early-stage breast cancer. (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Rationale for anthracycline- and taxane-containing regimen'</a> and  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Acceptable alternatives to anthracycline-based treatment'</a> and  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Choice of chemotherapy'</a>.)</p><p class="headingAnchor" id="H1476644752"><span class="h3">Neurotoxicity</span><span class="headingEndMark"> — </span>Taxanes such as <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> are associated with both a motor and sensory neuropathy that is dose and schedule dependent and cumulative [<a href="#rid2">2</a>]. For those receiving paclitaxel, grade 2 to 4 neuropathy occurs in 25 to 30 percent of patients, with grade 3 or 4 neuropathy occurring in 5 to 10 percent. For patients receiving docetaxel, grade 2 to 4 neuropathy occurs in 15 to 20 percent, and grade 3 or 4 neuropathy in approximately 5 percent [<a href="#rid3">3</a>]. Early recognition and subsequent treatment delay or dose reduction may alleviate or prevent the worsening of symptoms in most cases. Symptoms usually improve slowly after discontinuation of treatment (over weeks to months); if severe, recovery may be incomplete. In addition, paclitaxel can cause an acute pain syndrome in the first few days after administration, characterized by a diffuse aching discomfort that predominantly impacts the legs, hips, and back, though some patients may complain of more widespread pain [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Taxanes'</a>.)</p><p>Of available agents, <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">duloxetine</a> was shown to be effective in the treatment of chemotherapy-induced neuropathy. Other options including <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or a tricyclic antidepressant have not demonstrated clear benefit, but in the setting of limited options a therapeutic trial may be appropriate. These results are reviewed elsewhere. Dose reductions and dose holds are recommended for patients with cumulative symptom burden with functional deficits [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/94976.html" rel="external">"Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Treatment'</a>.)</p><p><a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">Paclitaxel</a> is associated with transient scintillating scotomas during infusion in approximately 20 percent of patients, which are typically self-limited. (See  <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy"</a>.)</p><p class="headingAnchor" id="H3081623036"><span class="h3">Pulmonary toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">Paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> are associated with pneumonitis in approximately 5 percent or less of patients. Concurrent administration of taxanes with checkpoint inhibitor therapy in early-stage breast cancer can be further associated with a higher risk of pulmonary toxicity [<a href="#rid6">6</a>]. Presentation is typically with dyspnea, cough, malaise, and/or low-grade fever. Nonspecific features of pneumonitis are typically seen on imaging. Although most cases are self-limited and resolve with discontinuation of taxane therapy, glucocorticoids are indicated in cases of severe pneumonitis. Further discussion of specific indications is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4355.html" rel="external">"Taxane-induced pulmonary toxicity", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H1555200936"><span class="h3">Hepatotoxicity</span><span class="headingEndMark"> — </span>Hepatotoxicity may be seen in up to one-third of patients receiving taxanes (more commonly <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>) [<a href="#rid7">7</a>], with higher incidence among those receiving concurrent immunotherapy [<a href="#rid6">6</a>]. For example, one study of patients receiving paclitaxel reported elevations in bilirubin in 8 percent, alkaline phosphatase in 23 percent, aspartate transaminase in 16 percent, and alanine transaminase in 33 percent [<a href="#rid8">8</a>]. It is typically mild, and in such cases, no interventions are required, although dose adjustments may be necessary. For more severe cases, discontinuation may be indicated. Given that both paclitaxel and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> are excreted by the liver, liver function abnormalities may increase nonhepatic toxicities, though no evidence suggests impaired efficacy of the agents. (See  <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Combination chemotherapy regimens'</a>.)</p><p class="headingAnchor" id="H2959752572"><span class="h3">Musculoskeletal side effects</span><span class="headingEndMark"> — </span>Dose-related myalgias and arthralgias are a particular problem with <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>; they typically develop between 72 and 96 hours of treatment and are much less common with weekly compared with every-three-week regimens [<a href="#rid9">9</a>]. The pathophysiologic mechanism is unknown; however, accumulating evidence supports the view that this is a manifestation of acute neurotoxicity (it is referred to as paclitaxel-associated acute pain syndrome) [<a href="#rid4">4</a>]. The onset of symptoms is associated with individual doses and does not appear to be a cumulative effect [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Clinical features, incidence, and risk factors'</a>.)</p><p>There is a paucity of data on prevention and treatment of this complication, but options for management include the use of nonsteroidal anti-inflammatory drugs, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a>, and antihistamines [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H3791058635"><span class="h2">Anthracyclines</span><span class="headingEndMark"> — </span>Anthracyclines are used frequently in early breast cancer. (See  <a class="medical medical_review" href="/z/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Anthracycline-based therapy'</a> and  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Rationale for anthracycline- and taxane-containing regimen'</a>.)</p><p>In the acute setting, anthracycline-containing regimens are associated with higher frequency of emesis relative to non-anthracycline-containing regimens, though rates are lower than historically due to newer antiemetics. Anthracyclines are also associated with mucositis, hand-foot syndrome, neutropenia, anemia, and complete alopecia. (See <a class="local">'Mucositis'</a> below and <a class="local">'Dermatologic toxicity'</a> below and <a class="local">'Myelosuppression'</a> below.)</p><p>A small number of patients may experience acute cardiotoxicity. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p>Long-term side effects include a small but higher incidence of cardiotoxicity and secondary malignancies relative to non-anthracycline-containing regimens.</p><p class="headingAnchor" id="H2343497810"><span class="h2">Capecitabine</span><span class="headingEndMark"> — </span>Adjuvant therapy with <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> is currently indicated in patients with high-risk, triple-negative breast cancer with residual disease after neoadjuvant chemotherapy [<a href="#rid11">11</a>]. Most common toxicities include fatigue, nausea, and diarrhea. Approximately two-thirds of patients receiving adjuvant capecitabine will experience hand-foot syndrome (pain, erythema, and/or blistering on the palms of the hands and soles of the feet) [<a href="#rid11">11</a>]. These are typically managed with standard symptom management strategies as well as dose reductions, which are very common with this regimen. Management of these toxicities is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Capecitabine'</a> and  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Capecitabine'</a> and  <a class="medical medical_review" href="/z/d/html/142102.html" rel="external">"Toxic erythema of chemotherapy (hand-foot syndrome)", section on 'Hand-foot syndrome'</a>.)</p><p>This agent is now commonly combined with immunotherapy, such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, which can be associated with additional immune-mediated toxicities. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H2566127271"><span class="h2">Carboplatin</span><span class="headingEndMark"> — </span>Several regimens in early-stage breast cancer utilize <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid12">12,13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>, and <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">Paclitaxel</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid14">14</a>]</p><p></p><p>The most common toxicities include fatigue, cytopenias, and nausea. Neuropathy and nephrotoxicity are less common. Management of toxicities associated with platinum agents if found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a>.)</p><p class="headingAnchor" id="H3835398966"><span class="h2">Cyclophosphamide</span><span class="headingEndMark"> — </span>In early-stage breast cancer, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is used in combination with anthracyclines, taxanes, and 5-fluorouracil. At the doses used in these regimens, the most common toxicities are nausea, cytopenia, ovarian insufficiency, and fatigue. Late toxicities can include a small risk of secondary hematologic malignancies. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases"</a> and  <a class="medical medical_review" href="/z/d/html/4349.html" rel="external">"Cyclophosphamide pulmonary toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Cyclophosphamide'</a>.)</p><p class="headingAnchor" id="H1112554173"><span class="h1">GENERAL ISSUES RELATED TO CHEMOTHERAPY</span></p><p class="headingAnchor" id="H5"><span class="h2">Myelosuppression</span></p><p class="headingAnchor" id="H603471458"><span class="h3">Neutropenia</span><span class="headingEndMark"> — </span>Most patients receiving combination chemotherapy experience a small to moderate reduction in the white blood cell count, 10 to 14 days after each cycle. It usually resolves prior to the next course of chemotherapy. However, if severe or prolonged, it can result in fever or life-threatening infection.</p><p>For most regimens used in breast cancer therapy, the risk of febrile neutropenia is less than 2 percent. However, there are several regimens associated with at least a 20 percent risk of neutropenia:</p><p class="bulletIndent1"><span class="glyph">●</span>Docetaxel-containing regimens (both TAC [<a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>] and TC [docetaxel, cyclophosphamide])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment every two weeks (ie, dose-dense, eg, ACT [<a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">Docetaxel</a> carboplatin-based regimen with or without HER2-targeted therapies (<a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> and <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a>)</p><p></p><p>Patients receiving either docetaxel-containing regimens or dose-dense chemotherapy regimens, and those who experienced neutropenic fever with their previously administered cycle, are treated with granulocyte colony stimulating factors (G-CSF) to reduce the duration of neutropenia and the risk of neutropenic fever [<a href="#rid15">15,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation", section on 'Primary prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation", section on 'Secondary prophylaxis'</a>.)</p><p class="headingAnchor" id="H2770336698"><span class="h3">Anemia</span><span class="headingEndMark"> — </span>A common side effect of chemotherapy is myelosuppression, including the onset of anemia. Anemia can impair a patient's functional status, diminish physiologic reserve, and result in significant fatigue.</p><p>While erythropoietin-stimulating agents (ESAs) are available for the treatment of anemia, their administration has been associated with increased risks for thromboembolic events and worse clinical outcomes, including survival. For women with early-stage breast cancer receiving chemotherapy with curative intent, we do not administer ESAs. Rather, for patients with a symptomatic anemia, we offer red blood cell transfusions, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Effect on disease control and survival'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Gastrointestinal side effects</span></p><p class="headingAnchor" id="H985144536"><span class="h3">Nausea and vomiting</span><span class="headingEndMark"> — </span>Although significant progress has been made, chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment. The dose-dense combination of <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is considered highly emetogenic (experienced by &gt;90 percent of patients) [<a href="#rid17">17</a>], whereas regimens containing either <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, or <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> are moderately emetogenic (experienced by 60 to 90 percent of patients). All patients receiving adjuvant chemotherapy require antiemetic therapy tailored to the risk of the specific treatment regimen [<a href="#rid18">18</a>]. Details of treatment are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H556222257"><span class="h3">Mucositis</span><span class="headingEndMark"> — </span>Patients at risk for mucositis and those who experienced mucositis with a prior cycle should receive oral cryotherapy (ice chips swished around the mouth for 30 minutes) around the time of drug administration. A variety of mucosal coating agents are available, including topical <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, oral antacids, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, and compounded mixtures, such as "miracle mouthwash," that combine such agents. Although data are lacking to support one of these agents over another, a therapeutic trial of any of these options is reasonable. The use of systemic antifungal therapy (ie, <a class="drug drug_general" data-topicid="9712" href="/z/d/drug information/9712.html" rel="external">nystatin</a> suspension or <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>) is not recommended. Further discussion is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1152.html" rel="external">"Oral toxicity associated with systemic anticancer therapy"</a>.)</p><p>Oral mucositis is the inflammation of the buccal mucosa or soft palate. It typically begins as a burning sensation in the mouth, but as it increases in severity, it can result in ulceration with an inability to eat or drink. Fortunately, the frequency of severe oropharyngeal mucositis or stomatitis and of diarrhea requiring intravenous-fluid therapy or hospitalization is low for regimens of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, largely because of the widespread use of G-CSF to prevent neutropenia. However, incidence of severe mucositis but may be higher when the regimen also includes <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (eg, cyclophosphamide, doxorubicin, and fluorouracil [CAF]) [<a href="#rid2">2</a>]. Higher risk of stomatitis or diarrhea is evident in multi-agent chemotherapy immunotherapy combination regimens [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H556222309"><span class="h3">Weight gain</span><span class="headingEndMark"> — </span>Up to 96 percent of women gain weight during treatment, and this appears to be particularly problematic among premenopausal women [<a href="#rid19">19</a>]. Potential mechanisms may involve energy imbalances provoked by chemotherapy, such as poor treatment tolerance, hormonal alterations, and changes in adiposity that may induce insulin resistance [<a href="#rid20">20</a>].</p><p>Because obesity has been associated with inferior outcomes in women treated for breast cancer, all patients receiving chemotherapy should meet with a nutritionist about diet and exercise programs during and after completion of chemotherapy [<a href="#rid21">21-23</a>].</p><p class="headingAnchor" id="H1989749243"><span class="h2">Dermatologic toxicity</span></p><p class="headingAnchor" id="H1803344796"><span class="h3">Cutaneous side effects</span><span class="headingEndMark"> — </span>Most patients tolerate adjuvant chemotherapy for breast cancer without notable dermatologic toxicities, although pigmentary changes caused by anthracyclines and taxanes have been reported. Hand-foot syndrome, associated with <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, is described above. (See <a class="local">'Capecitabine'</a> above.)</p><p>Other toxicities attributed to anthracyclines and <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> have been described, including nail changes such as discoloration, brittleness, ridging, and the nail coming off during treatment. In addition, subacute cutaneous lupus erythematosus as well as a variant of acral erythema called fixed erythrodysesthesia plaque occurring proximal to the infusion site can occur. (See  <a class="medical medical_review" href="/z/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents"</a>.)</p><p class="headingAnchor" id="H3793531327"><span class="h3">Alopecia</span><span class="headingEndMark"> — </span>The agents most commonly used in adjuvant therapy for breast cancer (eg, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>) are all associated with high frequency of alopecia. Therefore, options such as head wraps, hats, or wigs should be discussed in advance in order to prepare the patient for the likely outcome of hair loss.</p><p>For women with breast cancer who are receiving chemotherapy that is expected to result in significant alopecia, and who place a high value on avoidance of chemotherapy-induced alopecia, a scalp-cooling device is appropriate. Chemotherapy-induced alopecia and scalp cooling is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy", section on 'Scalp hypothermia (scalp cooling)'</a>.)</p><p>Hair thinning typically begins after the second or third cycle of treatment, with more substantial loss as treatment continues. Hair loss is typically transient, and regrowth typically occurs after cessation of therapy, although reduced density may be observed. The rates of alopecia not progressing to needing a hairpiece (wig) are about 75 percent with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> regimen (ie, TC), when scalp cooling is used. By contrast, with anthracycline-containing adjuvant chemotherapy, scalp cooling only prevents about one-half of women from needing a hairpiece due to alopecia. Additionally, the success of scalp cooling can be variable based on the ethnicity profile of the hair [<a href="#rid24">24,25</a>]. Although a scalp-cooling device is sanctioned by the US Food and Drug Administration, Medicare, Medicaid, and third-party payers do not universally cover the costs of this scalp-cooling device or other methods of scalp cooling, although depending on the coverage plan, some insurance coverage has been available to some patients.</p><p class="headingAnchor" id="H9"><span class="h2">Fatigue</span><span class="headingEndMark"> — </span>Moderate to severe fatigue is a common complaint during adjuvant chemotherapy [<a href="#rid26">26-28</a>]. Possible contributory factors include anemia and vasomotor symptoms that lead to sleep disturbance and depression [<a href="#rid29">29</a>]. For most patients, fatigue generally resolves following the completion of treatment [<a href="#rid30">30</a>]. However, some patients with early-stage breast cancer may have persistent fatigue symptoms after completion of treatment [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a>.)</p><p>Treatment of fatigue during therapy should begin with an evaluation for potentially correctable etiologic factors, including anemia, pain, depression, hypoxia, or fluid/electrolyte imbalances. In many cases, fatigue will not be attributable to a correctable condition, and treatment should be directed towards symptomatic relief. (See  <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">"Cancer-related fatigue: Treatment"</a>.)</p><p class="headingAnchor" id="H2193186820"><span class="h2">Sexual and reproductive side effects</span></p><p class="headingAnchor" id="H2755538611"><span class="h3">Vasomotor symptoms</span><span class="headingEndMark"> — </span>Vasomotor symptoms may develop because of premature cessation of ovarian function caused by the administration of adjuvant chemotherapy, or for those with hormone receptor-positive tumors, the use of adjuvant hormone therapy (<a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">anastrozole</a>, oophorectomy, gonadotropin-releasing hormone [GnRH] agonists). (See <a class="local">'Chemotherapy-induced amenorrhea'</a> below.)</p><p>The major clinical manifestations of vasomotor symptoms are hot flashes, sleep disturbance, headache, and irritability. The use of systemic estrogen replacement is generally prohibited because data from randomized trials suggest that estrogen therapy may be associated with excessive risk. Therefore, we recommend the use of non-estrogen therapies for controlling symptoms before considering estrogen therapy in these women. This is consistent with guidelines from the North American Menopause Society [<a href="#rid32">32</a>]. The risks of postmenopausal hormonal therapy in women with a prior history of breast cancer are covered separately. (See  <a class="medical medical_review" href="/z/d/html/7392.html" rel="external">"Menopausal hormone therapy and the risk of breast cancer", section on 'Personal history of breast cancer'</a>.)</p><p>Several non-estrogenic treatments such as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and the selective serotonin and norepinephrine reuptake inhibitors (SSRIs and SSNRIs, respectively) may provide symptomatic benefit for women with troublesome vasomotor symptoms. For those who will later initiate treatment with <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>, it should be noted that SSRIs and SSNRIs have inhibitory activity on CYP2D6, the liver enzyme that is responsible for converting tamoxifen to its active metabolite endoxifen. Although breast outcomes have not been shown to be worsened for those on other SSRIs or SSNRIs while on tamoxifen, we typically choose an agent with minimal inhibitory activity on CYP2D6 if initiating this type of therapy (eg, <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>). In addition, <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> is another possible option for patients with vasomotor symptoms [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'Intrinsic resistance'</a> and  <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">"Menopausal hot flashes"</a> and  <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Women with breast cancer'</a>.)</p><p>In addition to pharmacologic treatments, cognitive behavioral therapy (CBT) and exercise may alleviate the burden of vasomotor symptoms. In one trial, 422 women were randomly assigned to CBT, exercise, CBT plus exercise, or to a control group (no interventions) [<a href="#rid34">34</a>]. CBT consisted of six weekly group sessions that incorporated relaxation techniques. The exercise program was a 12-week individualized, home-based program that required 2.5 to 3 hours of activity per week. Of those who participated, 64 percent were ≤3 years out from completion of chemotherapy and 93 percent were still taking adjuvant endocrine therapy. High levels of noncompliance were reported (58, 64, and 70 percent in the CBT, exercise, and CBT plus exercise groups, respectively). When outcomes were analyzed using data from women who were compliant (n = 219), all three interventions resulted in significantly lower endocrine symptoms compared with controls at 12 weeks and 6 months. In addition, CBT with or without exercise significantly reduced the perceived burden associated with hot flashes or night sweats, which was sustained at six months.</p><p>The data supporting acupuncture for hot flashes in women with breast cancer have mixed results and further studies are necessary [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Inconsistent evidence of efficacy'</a>.)</p><p>Nevertheless, given lack of harm, it may be considered in breast cancer patients in whom pharmacologic therapy has been ineffective or for those who prefer to avoid taking medication for their hot flashes. However, access to qualified practitioners as well as limited insurance coverage has been challenging [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Chemotherapy-induced amenorrhea</span><span class="headingEndMark"> — </span>Chemotherapy-induced amenorrhea is a well-recognized side effect of cytotoxic chemotherapy. These drugs appear to have a greater effect on follicular development than on oocytes, with variable degrees of subsequent ovarian dysfunction. Some women develop complete follicular depletion and permanent ovarian failure during chemotherapy, while others become temporarily amenorrheic during therapy, with subsequent return of ovarian function, menstrual cycles, and fertility months to years after treatment cessation. (See  <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">"Overview of infertility and pregnancy outcome in cancer survivors"</a>.)</p><p>Amenorrhea is a poor surrogate for ovarian function and should not be considered as proof of menopause. For those with hormone receptor-positive disease, determining whether a patient is menopausal (versus amenorrheic, but not menopausal) after chemotherapy is an important issue, given that menopausal status influences the choice of endocrine therapy. This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Indications'</a> and  <a class="medical medical_review" href="/z/d/html/120706.html" rel="external">"Adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer", section on 'Transitioning from tamoxifen to an AI after menopause'</a> and  <a class="medical medical_review" href="/z/d/html/120706.html" rel="external">"Adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer", section on 'Definition of menopause'</a>.)</p><p class="headingAnchor" id="H556222552"><span class="h4">Risk factors</span><span class="headingEndMark"> — </span>There are well-recognized risk factors for chemotherapy-induced amenorrhea or ovarian failure, such as age, chemotherapy regimen, subsequent use of endocrine therapy, and genetics. These are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – The risk of amenorrhea is greater in women who are over the age of 40 at the time of treatment initiation  (<a class="graphic graphic_table graphicRef51143" href="/z/d/graphic/51143.html" rel="external">table 1</a>) [<a href="#rid38">38-40</a>]. In addition, ovarian failure is less often reversible in older women [<a href="#rid2">2,40,41</a>]. This was illustrated in a combined analysis of three trials of women (n = 796) treated with adjuvant doxorubicin-containing chemotherapy [<a href="#rid42">42</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Women under 30 years did not experience chemotherapy-induced amenorrhea.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapy-induced amenorrhea occurred in 96 percent of women age 40 to 49 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ovarian function (evidenced by resumption of menses) returned in 50 percent of women younger than 40 years, but only in 10 percent of women over 40 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy</strong> <strong>regimen</strong> – The incidence of chemotherapy-induced ovarian failure differs with the type of chemotherapy regimen. In a study evaluating amenorrhea following adjuvant chemotherapy in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B30 trial, the rates of prolonged amenorrhea (≥6 months) were lowest in the group treated with a regimen that did not contain <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (38 percent) and highest in those receiving a cyclophosphamide-containing treatment (70 percent) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">In general, rates of both transient and prolonged amenorrhea are higher with CMF or CEF/CAF-type regimens as compared with AC  (<a class="graphic graphic_table graphicRef51143" href="/z/d/graphic/51143.html" rel="external">table 1</a>) [<a href="#rid38">38,39,44</a>]. Although some trials evaluating the addition of taxanes report higher rates of prolonged amenorrhea than expected with AC alone, others suggest that rates are similar or even lower [<a href="#rid45">45-51</a>].</p><p></p><p class="bulletIndent1">The relative intensity of the chemotherapy regimen, including higher doses, longer duration, and the use of multi-agent regimens, confers higher rates of amenorrhea [<a href="#rid52">52</a>]. However, the impact of dose-dense therapy on rates of amenorrhea has not been well studied. The available data come from one prospective study of FEC administered on an every 14 or 21-day basis [<a href="#rid53">53</a>]. The incidence of amenorrhea was identical in both arms (64 percent). (See  <a class="medical medical_review" href="/z/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Importance of chemotherapy schedule'</a>.)</p><p></p><p class="bulletIndent1">Data are limited on the impact of newer targeted therapies and immunotherapies on ovarian function, although there is some evidence for detrimental impact on ovarian function [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic factors</strong> – Inherited genetic factors may play a role in determining which women will develop chemotherapy-induced amenorrhea or ovarian failure. Although not well studied, it is possible that genetic changes that have been associated with spontaneous premature menopause might also predict this complication [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p></p><p class="bulletIndent1">One category of candidate genes includes those involved in drug transport and metabolism [<a href="#rid56">56</a>]. CYP2C19 is an enzyme of the cytochrome P450 family that is involved in the metabolism of many drugs, including <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Although prospective studies have not been carried out, individuals receiving single-agent cyclophosphamide for lupus nephritis, who are homozygous or heterozygous for a CYP2C19 variant (CYP2C19*2), had a lower risk of ovarian failure (relative risk 0.10, 95% CI 0.02-0.52) after adjustment for age and total number of cyclophosphamide pulses [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">"General toxicity of cyclophosphamide in rheumatic diseases", section on 'Gonadal toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H556218357"><span class="h4">Menopausal symptoms</span><span class="headingEndMark"> — </span>Hot flashes, vaginal dryness, dyspareunia, depression, and sleep disturbance are often reported by postmenopausal women with breast cancer and can result in disruptions in quality of life during adjuvant therapy [<a href="#rid57">57,58</a>]. Successful management includes careful symptom assessment, education, counseling, and behavioral or pharmacologic interventions [<a href="#rid58">58</a>]. The treatment of menopausal symptoms is similar to the treatment of vasomotor symptoms, which is discussed above. (See <a class="local">'Vasomotor symptoms'</a> above.)</p><p>Management of vaginal dryness, including risks and benefits of topical estrogen therapy, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Sexual dysfunction'</a>.)</p><p class="headingAnchor" id="H556219926"><span class="h4">Infertility</span><span class="headingEndMark"> — </span>Breast cancer survivors have a lower rate of subsequent pregnancy than the general population. (See  <a class="medical medical_review" href="/z/d/html/4801.html" rel="external">"Overview of infertility and pregnancy outcome in cancer survivors"</a>.)</p><p>Because chemotherapy-induced amenorrhea is often transient and reversible (up to 24 months post-treatment), especially in younger women, sexually active women should be prescribed nonhormonal methods of birth control even if they are not menstruating because they may still ovulate and become pregnant. (See  <a class="medical medical_review" href="/z/d/html/15781.html" rel="external">"Approach to the patient following treatment for breast cancer", section on 'Contraception after breast cancer'</a>.)</p><p>Although administration of GnRH agonists has been studied as a way to prevent damage to ovarian tissue for patients undergoing chemotherapy, this issue is controversial and discussed in detail elsewhere. GnRH agonists may be offered to patients in the hope of reducing the likelihood of chemotherapy-induced ovarian insufficiency but should not be used in place of proven fertility preservation methods. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery", section on 'Breast cancer'</a>.)</p><p>Although women may experience the return of menstrual cycles after cessation of chemotherapy, this is not a good marker of normal ovarian function [<a href="#rid59">59</a>]. For women who are concerned about fertility during and after chemotherapy, testing for ovarian reserve is available. Serum measurement of anti-Müllerian hormone and inhibin B were found to correlate with chemotherapy-induced amenorrhea in a study of 127 patients [<a href="#rid60">60</a>]. However, data on the association of anti-müllerian hormones with future fertility outcomes after cancer treatment were limited [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H24"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/858.html" rel="external">"Patient education: Breast cancer guide to diagnosis and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/877.html" rel="external">"Patient education: Treatment of early HER2-positive breast cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10809655"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Adjuvant chemotherapy represents a significant advance in the management of early-stage breast cancer, resulting in many lives being saved. Although the acute toxicities must be considered when assessing the relative risk-benefit ratio of adjuvant chemotherapy, in general, the survival benefit gained exceeds the negative impact of side effects on quality of life in both premenopausal and postmenopausal women. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Issues related to specific agents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Taxanes</strong> – Taxanes, such as <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, are associated with both a motor and sensory neuropathy that is dose- and schedule-dependent and cumulative. Taxanes are also associated with pneumonitis in a minority of cases, as well as dose-related myalgias and arthralgias. (See <a class="local">'Taxanes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anthracyclines</strong> – Anthracycline-containing regimens are associated with higher frequency of emesis relative to non-anthracycline-containing regimens, though rates are lower than historically due to newer antiemetics. Anthracyclines are also associated with mucositis, hand-foot syndrome, neutropenia, anemia, and complete alopecia. A small number of patients may experience acute cardiotoxicity. (See <a class="local">'Anthracyclines'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">Capecitabine</a> – Most common toxicities include fatigue, nausea, and diarrhea. Approximately two-thirds of patients receiving adjuvant capecitabine will experience hand-foot syndrome. (See <a class="local">'Capecitabine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">Carboplatin</a> – The most common toxicities include fatigue, cytopenias, and nausea. (See <a class="local">'Carboplatin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> – The most common toxicities are nausea, cytopenia, ovarian insufficiency, and fatigue. Late toxicities can include a small risk of secondary hematologic malignancies. (See <a class="local">'Cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General issues related to chemotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nausea, vomiting, stomatitis (mucositis), and bone marrow suppression are acute and reversible side effects of systemic chemotherapy. (See <a class="local">'Gastrointestinal side effects'</a> above and <a class="local">'Myelosuppression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The agents most commonly used in adjuvant therapy for breast cancer are associated with a high frequency of alopecia. Hair loss is typically transient, and regrowth typically occurs after cessation of therapy, although reduced density may be observed. Chemotherapy-induced alopecia and scalp cooling is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy", section on 'Scalp hypothermia (scalp cooling)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe fatigue is a common complaint during adjuvant chemotherapy; contributory factors include anemia, vasomotor symptoms, and depression. (See <a class="local">'Fatigue'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasomotor symptoms may develop because of premature cessation of ovarian function caused by the administration of adjuvant chemotherapy or the use of adjuvant hormone therapy in women with hormone receptor-positive tumors. (See <a class="local">'Vasomotor symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapy-induced amenorrhea is a well-recognized side effect of cytotoxic chemotherapy. The frequency and duration vary according to age, the specific chemotherapy regimen, and use of endocrine therapy. The consequences of premature ovarian failure include menopausal symptoms and bone loss. (See <a class="local">'Chemotherapy-induced amenorrhea'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98:1108.</a></li><li><a class="nounderline abstract_t">Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344:1997.</a></li><li><a class="nounderline abstract_t">Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020; 38:3325.</a></li><li><a class="nounderline abstract_t">Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073.</a></li><li><a class="nounderline abstract_t">Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.</a></li><li><a class="nounderline abstract_t">Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381.</a></li><li><a class="nounderline abstract_t">Akerley W 3rd. Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest 2000; 117:152S.</a></li><li><a class="nounderline abstract_t">Garrison JA, McCune JS, Livingston RB, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park) 2003; 17:271.</a></li><li><a class="nounderline abstract_t">Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376:2147.</a></li><li><a class="nounderline abstract_t">Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 2018; 24:5820.</a></li><li><a class="nounderline abstract_t">Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clin Cancer Res 2017; 23:649.</a></li><li><a class="nounderline abstract_t">Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382:810.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, Version 1.2012 http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf (Accessed on May 21, 2012).</li><li><a class="nounderline abstract_t">Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.</a></li><li><a class="nounderline abstract_t">Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.</a></li><li><a class="nounderline abstract_t">Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.</a></li><li><a class="nounderline abstract_t">Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 2011; 12:282.</a></li><li><a class="nounderline abstract_t">Gadéa E, Thivat E, Planchat E, et al. Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes Rev 2012; 13:368.</a></li><li><a class="nounderline abstract_t">Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 2011; 50:167.</a></li><li><a class="nounderline abstract_t">Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243.</a></li><li><a class="nounderline abstract_t">Ligibel JA, Bohlke K, May AM, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022; 40:2491.</a></li><li><a class="nounderline abstract_t">Araoye EF, Stearns V, Aguh C. Considerations for the Use of Scalp Cooling Devices in Black Patients. J Clin Oncol 2020; 38:3575.</a></li><li><a class="nounderline abstract_t">Dilawari A, Gallagher C, Alintah P, et al. Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? Oncologist 2021; 26:292.</a></li><li><a class="nounderline abstract_t">Sadler IJ, Jacobsen PB. Progress in understanding fatigue associated with breast cancer treatment. Cancer Invest 2001; 19:723.</a></li><li><a class="nounderline abstract_t">Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 1998; 25:51.</a></li><li><a class="nounderline abstract_t">Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23:8025.</a></li><li><a class="nounderline abstract_t">Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998; 16:1689.</a></li><li><a class="nounderline abstract_t">Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18:743.</a></li><li><a class="nounderline abstract_t">Vaz-Luis I, Di Meglio A, Havas J, et al. Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. J Clin Oncol 2022; 40:2148.</a></li><li><a class="nounderline abstract_t">North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.</a></li><li><a class="nounderline abstract_t">Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr 2020; 4:pkz088.</a></li><li><a class="nounderline abstract_t">Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012; 30:4124.</a></li><li><a class="nounderline abstract_t">Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013; :CD007410.</a></li><li><a class="nounderline abstract_t">Jang S, Ko Y, Sasaki Y, et al. Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients: Systematic review and meta-analysis (PRISMA-compliant). Medicine (Baltimore) 2020; 99:e21820.</a></li><li><a class="nounderline abstract_t">Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin 2017; 67:194.</a></li><li><a class="nounderline abstract_t">Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24:5769.</a></li><li><a class="nounderline abstract_t">Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24:1045.</a></li><li><a class="nounderline abstract_t">Schmid P, Untch M, Kossé V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007; 25:2509.</a></li><li><a class="nounderline abstract_t">Bernard-Marty C, Mano M, Paesmans M, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003; 14:693.</a></li><li><a class="nounderline abstract_t">Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; :105.</a></li><li><a class="nounderline abstract_t">Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29:1110.</a></li><li><a class="nounderline abstract_t">Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol 2005; 23:6002.</a></li><li><a class="nounderline abstract_t">Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302.</a></li><li><a class="nounderline abstract_t">Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009; 113:315.</a></li><li><a class="nounderline abstract_t">Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007; 30:126.</a></li><li><a class="nounderline abstract_t">Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116:791.</a></li><li><a class="nounderline abstract_t">Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 2005; 6:421.</a></li><li><a class="nounderline abstract_t">Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104:1575.</a></li><li><a class="nounderline abstract_t">Berliere M, Dalenc F, Malingret N, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008; 8:56.</a></li><li><a class="nounderline abstract_t">Hulvat MC, Jeruss JS. Fertility preservation options for young women with breast cancer. Curr Opin Obstet Gynecol 2011; 23:174.</a></li><li><a class="nounderline abstract_t">Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97:1724.</a></li><li><a class="nounderline abstract_t">Duma N, Lambertini M. It Is Time to Talk About Fertility and Immunotherapy. Oncologist 2020; 25:277.</a></li><li><a class="nounderline abstract_t">Stearns V, Schneider B, Henry NL, et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006; 6:886.</a></li><li><a class="nounderline abstract_t">Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202.</a></li><li><a class="nounderline abstract_t">Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008; 26:753.</a></li><li><a class="nounderline abstract_t">Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 2007; 29:230.</a></li><li><a class="nounderline abstract_t">Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol 2010; 35:259.</a></li><li><a class="nounderline abstract_t">Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010; 116:592.</a></li><li><a class="nounderline abstract_t">Anderson RA, Cameron D, Clatot F, et al. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update 2022; 28:417.</a></li></ol></div><div id="topicVersionRevision">Topic 745 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912263" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11430330" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Side effects of adjuvant treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420499" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Weekly paclitaxel in the adjuvant treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383290" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32663120" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724392" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473644" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatotoxicity of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7627725" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Taxanes: a new class of antitumor agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777471" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12632867" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Myalgias and arthralgias associated with paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28564564" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30061361" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27301700" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101663" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pembrolizumab for Early Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101663" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pembrolizumab for Early Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26169616" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antiemetics: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525044" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880127" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Weight gain in breast cancer survivors: prevalence, pattern and health consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133030" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091401" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Updated evidence in support of diet and exercise interventions in cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22539238" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nutrition and physical activity guidelines for cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576506" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32897824" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Considerations for the Use of Scalp Cooling Devices in Black Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512741" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11577813" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Progress in understanding fatigue associated with breast cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9460773" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258100" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586880" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673515" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35290073" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154637" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337497" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045575" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897589" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Acupuncture for menopausal hot flushes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327222" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients: Systematic review and meta-analysis (PRISMA-compliant).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436999" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17130515" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16476708" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577027" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702521" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3534581" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300930" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135468" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930421" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjuvant docetaxel for node-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302020" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414460" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20052714" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16381625" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16134178" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18291033" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415746" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fertility preservation options for young women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16333028" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32091651" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : It Is Time to Talk About Fertility and Immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17036039" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15248218" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258983" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472816" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21178920" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Measuring ovarian function in young cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19918920" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35199161" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
